9.05

2.27% -0.21

Phathom Pharmaceuticals Inc (PHAT)

Overview News Price History Option Chain Financials Discussions Forecast

Phathom Pharmaceuticals Inc stock is traded at $9.05, with a volume of 663.05K. It is down -2.27% in the last 24 hours and up +0.78% over the past month. Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Previous Close:

$9.26

Open:

$9.3

24h Volume:

663.05K

Relative Volume:

0.51

Market Cap:

$732.15M

Revenue:

$204.89M

Net Income/Loss:

$-157.30M

P/E Ratio:

-4.2869

EPS:

-2.1111

Net Cash Flow:

$-97.76M

1W Performance:

+1.23%

1M Performance:

+0.78%

6M Performance:

-18.10%

1Y Performance:

-23.82%

1-Day Range:

$8.984

$9.3113

1-Week Range:

$8.7816

$9.7296

52-Week Range:

$8.21

$18.31

Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile

Name

Phathom Pharmaceuticals Inc

Sector

Healthcare (1075)

Industry

Biotechnology (600)

Phone

(877) 742-8466

Address

100 CAMPUS DRIVE,, FLORHAM PARK, NJ

Employee

371

Twitter

Next Earnings Date

2026-07-30

Latest SEC Filings

PHAT's Discussions on Twitter

Compare PHAT vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PHAT Phathom Pharmaceuticals Inc	9.05	695.75M	204.89M	-157.30M	-97.76M	-2.1111
VRTX Vertex Pharmaceuticals Inc	557.96	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	843.47	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,053.46	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	148.87	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.87	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-27-26	Upgrade	Barclays	Equal Weight → Overweight
Dec-12-25	Initiated	Raymond James	Strong Buy
Dec-09-25	Initiated	Barclays	Equal Weight
Feb-14-25	Initiated	Cantor Fitzgerald	Overweight
May-03-24	Initiated	Stifel	Buy
Jan-05-24	Reiterated	Needham	Buy
Aug-09-23	Initiated	H.C. Wainwright	Buy
May-11-23	Upgrade	Evercore ISI	In-line → Outperform
Mar-13-23	Initiated	Craig Hallum	Buy
Oct-21-22	Initiated	Jefferies	Buy
May-06-22	Downgrade	Evercore ISI	Outperform → In-line
May-12-21	Upgrade	Goldman	Sell → Neutral
Feb-17-21	Initiated	BMO Capital Markets	Outperform
Feb-02-21	Initiated	Guggenheim	Buy
Jun-26-20	Downgrade	Goldman	Neutral → Sell
Nov-20-19	Initiated	Evercore ISI	Outperform
Nov-19-19	Initiated	Goldman	Neutral
Nov-19-19	Initiated	Jefferies	Buy
Nov-19-19	Initiated	Needham	Buy

View All

Phathom Pharmaceuticals Inc Stock (PHAT) Latest News

Aug 20, 2026

Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 8.2%What's Next? - MarketBeat

Aug 20, 2026

Aug 18, 2026

PHAT Stock Clocks Worst Day In Over 1.5 Years — What Sparked The Selloff? - Stocktwits

Aug 18, 2026

3,496,808 Shares in Phathom Pharmaceuticals, Inc. $PHAT Acquired by Carlyle Group Inc. - MarketBeat

Aug 18, 2026

Aug 17, 2026

PHAT Maintains Overweight Rating -- Price Target Lowered to $14 - GuruFocus

Aug 17, 2026

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Aug 17, 2026

Aug 16, 2026

Phathom Pharmaceuticals (PHAT) Advances 4.36% to $9.58, Approaches Key Resistance at $10.06MESA MA - vinanet.vn

Aug 16, 2026

Phathom Pharmaceuticals (PHAT) Stock Sees Modest Fair Value Cut After Analyst Target Cuts - Yahoo Finance

Aug 16, 2026

Aug 14, 2026